The Open Respiratory Medicine Journal


ISSN: 1874-3064 ― Volume 11, 2017

Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis



Shoaib Faruqi*, Dejene Shiferaw, Alyn H. Morice
Department of Respiratory Medicine, Castle Hill Hospital, Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Yorkshire, UK

Abstract

Background and Objectives:

Cough is a major symptom in cystic fibrosis. Ivacaftor is a novel drug which targets the G551D mutation and has been demonstrated to improve lung function and weight in the long term. It also improves symptoms of extra-oesophageal reflux. We wanted to evaluate the effect of ivacaftor on cough in cystic fibrosis.

Methods:

In two patients with cystic fibrosis the Hull Airway Reflux Questionnaire (HARQ) was completed and objective cough counts were measured prior to and within 4 weeks after initiation of treatment with ivacaftor. Spirometry was also undertaken and weight checked at these time frames.

Results:

In the first patient the HARQ score decreased from 29 to 11 and objective cough counts from 29 to 9 cough events per hour. Similarly in the second patient the HARQ score decreased from 13 to 9 and objective cough count from 76 to 5 cough events per hour. There was no significant change in spirometric parameters or weight.

Conclusion:

We have observed early subjective and objective improvement in cough measures on treatment with ivacaftor. We suggest that this improvement could be attributed to improvement of gastro-intestinal function and that cough metrics could be used as early and accurate end points of drug efficacy.

Keywords: Cystic fibrosis, Cough, Ivacaftor, Gastro-oesophageal reflux, G551D mutation, Lung function.


Article Information


Identifiers and Pagination:

Year: 2016
Volume: 10
First Page: 105
Last Page: 108
Publisher Id: TORMJ-10-105
DOI: 10.2174/1874306401610010105

Article History:

Received Date: 10/11/2016
Revision Received Date: 14/11/2016
Acceptance Date: 14/11/2016
Electronic publication date: 30/12/2016
Collection year: 2016

Article Metrics:

Total Statistics:

Full-Text HTML Views: 4
Abstract HTML Views: 14
PDF Downloads: 3
ePub Downloads: 3
Total Views/Downloads: 24

Unique Statistics:

Full-Text HTML Views: 4
Abstract HTML Views: 11
PDF Downloads: 3
ePub Downloads: 3
Total Views/Downloads: 21
Geographical View

© Faruqi et al.; Licensee Bentham Open

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.


* Address correspondence to this author at the Department of Respiratory Medicine, Castle Hill Hospital, Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Yorkshire, United Kingdom; Fax: 01482624068l; Email: shoaib.faruqi@hey.nhs.uk




INTRODUCTION

Cough is one of the predominant symptoms in cystic fibrosis. Patients frequently describe a dry, non-productive background cough with “infective” exacerbations. Ivacaftor is a novel cystic fibrosis transmembrane conductance regulator (CFTR) potentiator targeting the G551D mutation. It has been shown to increase weight and improve lung function in a randomised study [1Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663-72.
[http://dx.doi.org/10.1056/NEJMoa1105185] [PMID: 22047557]
]; however these parameters are unsuitable for short term efficacy assessments. Objective and subjective measures of cough could potentially act as a rapidly responsive, clinically relevant endpoint for establishing the effectiveness of this class of drugs. We observed the objective and subjective cough response in two cystic fibrosis patients with G551D mutation, following initiation of ivacaftor.

CASE 1

A 55 year old man with cystic fibrosis complained of prominent cough triggered by lying down, bending over, speaking and on rising from the bed. He suffered bloating, erratic bowel habit and mild dyspepsia. He previously had a Nissen fundoplication for airways reflux. His baseline FEV1 was 0.85 litres (25% predicted), weight 68.9 kg and Hull Airway Reflux Questionnaire (HARQ) score of 29 (the upper limit of normal is <13) [2Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM. Cough hypersensitivity syndrome: a distinct clinical entity. Lung 2011; 189(1): 73-9.
[http://dx.doi.org/10.1007/s00408-010-9272-1] [PMID: 21240613]
]. Baseline cough monitoring with the semi-automated Hull Automated Cough Counter HACC [3Barry SJ, Dane AD, Morice AH, Walmsley AD. The automatic recognition and counting of cough. Cough 2006; 2: 8.
[http://dx.doi.org/10.1186/1745-9974-2-8] [PMID: 17007636]
, 4Crooks MG, Hayman Y, Innes A, Williamson J, Wright CE, Morice AH. Objective measurement of cough frequency during COPD exacerbation convalescence. Lung 2016; 194(1): 117-20.
[http://dx.doi.org/10.1007/s00408-015-9782-y] [PMID: 26280405]
] demonstrated an average of 29 cough events per hour. Within 2 weeks of starting treatment with Ivacaftor he felt significant subjective improvement in his cough. This was reflected in the repeat HACC measurement of 9 coughs per hour (Fig. 1). The HARQ score concomitantly decreased to 11. FEV1 and weight were unchanged.

Fig. (1)
Twenty four hour cough recordings for both the patients before and after treatment with ivacaftor are depicted. Numbers of coughs recorded in an hour are shown on the “y” axis and the “x” axis demonstrates time in a 24 hour format. The top most panel is a cough recording for the first patient before treatment and the panel below that is on treatment with ivacaftor. The subsequent two panels similarly show the 24 hour cough recording for the second patient prior to (3rd panel from top) and on treatment (the last panel) with ivacaftor.


CASE 2

An unrelated 35 year old man with cystic fibrosis had similar prominent cough despite Nissen fundoplication. He had baseline FEV1 of 4.64 litres (112% predicted), weight of 63.8 kg, HARQ score of 13 and 76 cough events per hour were observed on cough monitoring. He spontaneously reported a subjective improvement in cough and his cough monitoring improved to 5 cough events per hour (Fig. 1). The subjective HARQ score was 9 after one month therapy with ivacaftor. Again there was no spirometric or weight change at his follow up visit.

DISCUSSION

Cystic fibrosis is a multi-system progressive disease with prominent pulmonary manifestations. With progressive pulmonary disease cough is a symptom which is reported by virtually all patients. There are several known pulmonary causes of cough in this patient group such as bronchiectasis, bacterial colonisation and airway inflammation. Gastro-oesophageal reflux (GER) is a common cause of chronic cough in the general population. High prevalence of GER and other non-acid symptoms of extra-oesophageal reflux have been reported in the CF population [5Pauwels A, Blondeau K, Mertens V, et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Aliment Pharmacol Ther 2011; 34(7): 799-807.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04786.x] [PMID: 21793864]
]. It has also been reported that surgical treatment of reflux leads to improvement of cough in this patient group, suggesting airway reflux to be an important cause for cough [6Fathi H, Moon T, Donaldson J, Jackson W, Sedman P, Morice AH. Cough in adult cystic fibrosis: diagnosis and response to fundoplication. Cough 2009; 5(1): 1.
[http://dx.doi.org/10.1186/1745-9974-5-1] [PMID: 19149907]
].

The HARQ is a self –administered 14-point questionnaire and is a validated tool for the diagnosis and quantification of the symptoms of airway reflux. In our validation study in chronic cough the upper limit of normal was a score of 13 and both our subjects had baseline values demonstrating significant abnormalities. Airway reflux consists of both acid and non-acid aerosolised mist which when deposited in the upper airway may lead to afferent neuronal hypersensitivity, recently termed the Cough Hypersensitivity Syndrome.

The objective assessment of chronic cough has been enhanced by the development of ambulatory cough monitoring systems and this form of assessment may represent the best global objective synthesis of cough, compared to other forms of objective and subjective assessment of cough [7Faruqi S, Thompson R, Wright C, Sheedy W, Morice AH. Quantifying chronic cough: objective versus subjective measurements. Respirology 2011; 16(2): 314-20.
[http://dx.doi.org/10.1111/j.1440-1843.2010.01893.x] [PMID: 21054670]
]. Twenty-four hour cough monitoring of both our subjects was well above normal at baseline. We show a very clear and early improvement in cough counts after starting ivacaftor despite no change in weight or spirometry. Hence, cough measurement could be used as an early, precise and clinically relevant endpoint in future drugs development. It may also prove useful as a monitor of compliance for these expensive new agents.

Ivacaftor has a marked positive impact in those with the G551D mutation with sustained improvements in lung function and particularly weight gain. Apart from the formal clinical trial itself, data gained from post approval use of ivacaftor also confirm this effect. Ivacaftor, by universally improving CFTR function, will act on the gastrointestinal tract as is evidenced by weight gain in long term therapy. Zybel et al. have recently reported the novel finding that treatment with ivacaftor leads to sustained and early improvement in symptoms of extra-oesophageal reflux using a panel of validated questionnaires including the HARQ [8Zeybel GL, Pearson JP, Krishnan A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros 2016; 30: pii: S1569-1993-.]. This symptomatic improvement occurred concurrently with a long-term improvement in weight and lung function. We suggest that the improvement in cough metrics seen in our patients reflects a global improvement of GI function in cystic fibrosis with disease modifying therapy.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663-72.
[http://dx.doi.org/10.1056/NEJMoa1105185] [PMID: 22047557]
[2] Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM. Cough hypersensitivity syndrome: a distinct clinical entity. Lung 2011; 189(1): 73-9.
[http://dx.doi.org/10.1007/s00408-010-9272-1] [PMID: 21240613]
[3] Barry SJ, Dane AD, Morice AH, Walmsley AD. The automatic recognition and counting of cough. Cough 2006; 2: 8.
[http://dx.doi.org/10.1186/1745-9974-2-8] [PMID: 17007636]
[4] Crooks MG, Hayman Y, Innes A, Williamson J, Wright CE, Morice AH. Objective measurement of cough frequency during COPD exacerbation convalescence. Lung 2016; 194(1): 117-20.
[http://dx.doi.org/10.1007/s00408-015-9782-y] [PMID: 26280405]
[5] Pauwels A, Blondeau K, Mertens V, et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Aliment Pharmacol Ther 2011; 34(7): 799-807.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04786.x] [PMID: 21793864]
[6] Fathi H, Moon T, Donaldson J, Jackson W, Sedman P, Morice AH. Cough in adult cystic fibrosis: diagnosis and response to fundoplication. Cough 2009; 5(1): 1.
[http://dx.doi.org/10.1186/1745-9974-5-1] [PMID: 19149907]
[7] Faruqi S, Thompson R, Wright C, Sheedy W, Morice AH. Quantifying chronic cough: objective versus subjective measurements. Respirology 2011; 16(2): 314-20.
[http://dx.doi.org/10.1111/j.1440-1843.2010.01893.x] [PMID: 21054670]
[8] Zeybel GL, Pearson JP, Krishnan A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros 2016; 30: pii: S1569-1993-.

Endorsements



"Open access will revolutionize 21st century knowledge work and accelerate the diffusion of ideas and evidence that support just in time learning and the evolution of thinking in a number of disciplines."


Daniel Pesut
(Indiana University School of Nursing, USA)

"It is important that students and researchers from all over the world can have easy access to relevant, high-standard and timely scientific information. This is exactly what Open Access Journals provide and this is the reason why I support this endeavor."


Jacques Descotes
(Centre Antipoison-Centre de Pharmacovigilance, France)

"Publishing research articles is the key for future scientific progress. Open Access publishing is therefore of utmost importance for wider dissemination of information, and will help serving the best interest of the scientific community."


Patrice Talaga
(UCB S.A., Belgium)

"Open access journals are a novel concept in the medical literature. They offer accessible information to a wide variety of individuals, including physicians, medical students, clinical investigators, and the general public. They are an outstanding source of medical and scientific information."


Jeffrey M. Weinberg
(St. Luke's-Roosevelt Hospital Center, USA)

"Open access journals are extremely useful for graduate students, investigators and all other interested persons to read important scientific articles and subscribe scientific journals. Indeed, the research articles span a wide range of area and of high quality. This is specially a must for researchers belonging to institutions with limited library facility and funding to subscribe scientific journals."


Debomoy K. Lahiri
(Indiana University School of Medicine, USA)

"Open access journals represent a major break-through in publishing. They provide easy access to the latest research on a wide variety of issues. Relevant and timely articles are made available in a fraction of the time taken by more conventional publishers. Articles are of uniformly high quality and written by the world's leading authorities."


Robert Looney
(Naval Postgraduate School, USA)

"Open access journals have transformed the way scientific data is published and disseminated: particularly, whilst ensuring a high quality standard and transparency in the editorial process, they have increased the access to the scientific literature by those researchers that have limited library support or that are working on small budgets."


Richard Reithinger
(Westat, USA)

"Not only do open access journals greatly improve the access to high quality information for scientists in the developing world, it also provides extra exposure for our papers."


J. Ferwerda
(University of Oxford, UK)

"Open Access 'Chemistry' Journals allow the dissemination of knowledge at your finger tips without paying for the scientific content."


Sean L. Kitson
(Almac Sciences, Northern Ireland)

"In principle, all scientific journals should have open access, as should be science itself. Open access journals are very helpful for students, researchers and the general public including people from institutions which do not have library or cannot afford to subscribe scientific journals. The articles are high standard and cover a wide area."


Hubert Wolterbeek
(Delft University of Technology, The Netherlands)

"The widest possible diffusion of information is critical for the advancement of science. In this perspective, open access journals are instrumental in fostering researches and achievements."


Alessandro Laviano
(Sapienza - University of Rome, Italy)

"Open access journals are very useful for all scientists as they can have quick information in the different fields of science."


Philippe Hernigou
(Paris University, France)

"There are many scientists who can not afford the rather expensive subscriptions to scientific journals. Open access journals offer a good alternative for free access to good quality scientific information."


Fidel Toldrá
(Instituto de Agroquimica y Tecnologia de Alimentos, Spain)

"Open access journals have become a fundamental tool for students, researchers, patients and the general public. Many people from institutions which do not have library or cannot afford to subscribe scientific journals benefit of them on a daily basis. The articles are among the best and cover most scientific areas."


M. Bendandi
(University Clinic of Navarre, Spain)

"These journals provide researchers with a platform for rapid, open access scientific communication. The articles are of high quality and broad scope."


Peter Chiba
(University of Vienna, Austria)

"Open access journals are probably one of the most important contributions to promote and diffuse science worldwide."


Jaime Sampaio
(University of Trás-os-Montes e Alto Douro, Portugal)

"Open access journals make up a new and rather revolutionary way to scientific publication. This option opens several quite interesting possibilities to disseminate openly and freely new knowledge and even to facilitate interpersonal communication among scientists."


Eduardo A. Castro
(INIFTA, Argentina)

"Open access journals are freely available online throughout the world, for you to read, download, copy, distribute, and use. The articles published in the open access journals are high quality and cover a wide range of fields."


Kenji Hashimoto
(Chiba University, Japan)

"Open Access journals offer an innovative and efficient way of publication for academics and professionals in a wide range of disciplines. The papers published are of high quality after rigorous peer review and they are Indexed in: major international databases. I read Open Access journals to keep abreast of the recent development in my field of study."


Daniel Shek
(Chinese University of Hong Kong, Hong Kong)

"It is a modern trend for publishers to establish open access journals. Researchers, faculty members, and students will be greatly benefited by the new journals of Bentham Science Publishers Ltd. in this category."


Jih Ru Hwu
(National Central University, Taiwan)


Browse Contents


Webmaster Contact: info@benthamopen.com
Copyright © 2017 Bentham Open